# Nivolumab and Dasatinib in Treating Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

> **NCT02819804** · PHASE1 · TERMINATED · sponsor: **Northwestern University** · enrollment: 1 (actual)

## Conditions studied

- B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1
- Recurrent Adult Acute Lymphoblastic Leukemia
- Recurrent Childhood Acute Lymphoblastic Leukemia
- Refractory Adult Acute Lymphoblastic Leukemia
- Refractory Childhood Acute Lymphoblastic Leukemia

## Interventions

- **DRUG:** Dasatinib
- **OTHER:** Laboratory Biomarker Analysis
- **BIOLOGICAL:** Nivolumab
- **OTHER:** Pharmacological Study

## Key facts

- **NCT ID:** NCT02819804
- **Lead sponsor:** Northwestern University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-08-17
- **Primary completion:** 2017-08-27
- **Final completion:** 2018-08-30
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Due to funding and accrual issues
- **Last updated:** 2020-02-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02819804

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02819804, "Nivolumab and Dasatinib in Treating Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02819804. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*